Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Melanoma

VEGF receptor 2 (KDR/Flk-1; VEGFR-2)

Mouse studies suggest co-delivery of engineered T cells expressing a chimeric antigen receptor (CAR) targeting VEGFR-2 and engineered T cells expressing tumor-specific T cell receptors (TCRs) could help treat melanoma. In lymphodepleted mice with established melanoma tumors, adoptive transfer of the two T cell populations plus a protocol to stimulate the transferred cells led to complete tumor regression and long-term, tumor-free survival. Next steps include dose-escalation safety studies of the anti-VEGFR-2, CAR-expressing T cells in patients.

SciBX 6(22); doi:10.1038/scibx.2013.545
Published online June 6, 2013

Patent application filed; available for licensing

Chinnasamy, D. et al. Cancer Res.; published online April 30, 2013;
doi:10.1158/0008-5472.CAN-12-3913
Contact: Steven A. Rosenberg, National Institutes of Health, Bethesda, Md.
e-mail:
sar@mail.nih.gov